Current genetic test for ovarian cancer

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(1), P. 8 - 10

Published: Jan. 1, 2025

Language: Английский

---

Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I)

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(5), P. 637 - 650

Published: Sept. 1, 2024

The WHO (World Health Organization) conducted an elimination of cervical cancer program using triple pillar intervention strategy to target 90%-70%-90% women before the year 2030, including (1) a full vaccination HPV (human papillomavirus) vaccine 90% girls <15 years age; (2) high-performance screening procedure 70% during reproductive age (at 35 and 45 age); (3) appropriate adequate treatment with confirmed diagnosis lesions. Among aforementioned three pillars, has been introduced in our previous review, which we have discussed policy world also reviewed efficacy vaccination, successful reduction over HPV-associated neoplasms. aims current review will another pillar-an Since early-stage favorable outcome recommendation established, therefore, focuses on persistent, recurrent metastatic cancers (advanced cancers), are still biggest challenge based its extremely worse outcomes introduction immune checkpoint inhibitors (ICIs). Integration ICIs into conventional chemotherapy (paclitaxel-cisplatin) become new standard therapy for those patients advanced cancers. recent clinical trials, such as KENOTE 826 A18 showing dramatical improvement both progression free survival overall approved therapeutic this combination ICI plus paclitaxel-platinum (cisplatin or carboplatin) with/without bevacizumab

Language: Английский

---

Surgery-based radiation-free multimodality treatment for locally advanced cervical cancer

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(5), P. 651 - 664

Published: Sept. 1, 2024

The current review described a 55-year woman using 28 months to finish her surgery-based radiation-free multimodality treatment journey fight International Federation of Gynaecology & Obstetrics (FIGO) 2018 clinical stage IIA2 (cT2aN0M0) squamous cell carcinoma (SCC) the cervix. She received six cycles perioperative adjuvant therapy, including three neoadjuvant therapy (NAT) and postoperative by combination dose-dense chemotherapy (CT, weekly paclitaxel 80 mg/m

Language: Английский

---

Cervical cancer: Part I human papilloma virus vaccination in Taiwan

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(3), P. 320 - 328

Published: May 1, 2024

A significant decline in both incidence and prevalence of cervical cancers after widespread-introducing screening strategy by Papanicolau test (Pap test) has been found the world, but cancer is still one most common female cancers, reporting fourth also leading causes to result main women-associated morbidity mortality, particularly for those women living low- middle-income countries. Cervical important health concerns directly destroying global health-care system, partly because not only increasing disability either secondary diseases themselves victims or mediated treatment-related adverse events survivors acting as a cause death diseased patients worldwide, alarming urgent need do something minimize catastrophic diseases-related heavy socioeconomic burden. It fortunate that preventable disease, based on its strong association with human papillomavirus (HPV) infection (more than 95%), high-risk HPV (HR-HPV) high possibility detecting before development well an effective prevention vaccination. That why WHO (World Health Organization) considers public problem attempts accelerate elimination program three-pillar approach (90:70:90% targets), including (1) 90% girls are fully vaccinated vaccine 15 years age; (2) 70% screened high-performance 35 45 age precancerous lesions treated early; (3) identified receive appropriate adequate treatment. Herein, this review focuses vaccination Part I, recommendations Taiwan government's policy

Language: Английский

---

The selection of immune checkpoint inhibitors of programmed cell death (anti-PD-1) and its ligand (anti-PD-L1) makes matters more challenges for clinical practice

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(4), P. 448 - 450

Published: July 1, 2024

Language: Английский

---

Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part VI

Journal of the Chinese Medical Association, Journal Year: 2024, Volume and Issue: 87(10), P. 901 - 903

Published: Aug. 2, 2024

Language: Английский

---

Antibody–drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (II): Anti-HER2/neu

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(6), P. 820 - 822

Published: Oct. 30, 2024

Language: Английский

---

Antibody–drug conjugates (ADCs) may be a big breakthrough in gynecologic cancer treatment (I)

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 63(6), P. 817 - 819

Published: Oct. 30, 2024

Language: Английский

---

Lymphedema and sentinel lymph node mapping

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(1), P. 4 - 5

Published: Jan. 1, 2025

Language: Английский

---

Primary cytoreductive surgery for advanced epithelial ovarian cancer patients is still popular in gynecologic oncologists in Korea and Taiwan, particularly apparent in Taiwan

Taiwanese Journal of Obstetrics and Gynecology, Journal Year: 2025, Volume and Issue: 64(1), P. 1 - 3

Published: Jan. 1, 2025

Language: Английский

---